Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report
暂无分享,去创建一个
L. Massuger | A. V. van Altena | J. Textor | I. D. de Vries | M. Gorris | T. Roelofsen | L. Massuger | C. Wefers
[1] V. Badovinac,et al. Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival , 2019, The Journal of Immunology.
[2] Keunchil Park,et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. , 2018, The Lancet. Oncology.
[3] B. Nelson,et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study , 2018, Oncoimmunology.
[4] J. Vincent,et al. Mechanisms and treatment of organ failure in sepsis , 2018, Nature Reviews Nephrology.
[5] Brian J. Stevenson,et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer , 2018, Science Translational Medicine.
[6] K. Kelly,et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials , 2018, Cancer.
[7] D. Rimm,et al. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement , 2018, Clinical Cancer Research.
[8] Inge M. N. Wortel,et al. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment , 2018, The Journal of Immunology.
[9] D. Matei,et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. , 2017 .
[10] M. Netea,et al. The immunopathology of sepsis and potential therapeutic targets , 2017, Nature Reviews Immunology.
[11] T. Randall,et al. Ovarian cancer and the immune system - The role of targeted therapies. , 2016, Gynecologic oncology.
[12] K. Kelly,et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. , 2016 .
[13] M. Morgan,et al. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. , 2016 .
[14] I. Christensen,et al. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma , 2015, Cancer Immunology, Immunotherapy.
[15] K. Yamaguchi,et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Donia,et al. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.
[17] R. Torensma,et al. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence. , 2015, Gynecologic oncology.
[18] R. Hotchkiss,et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.
[19] R. Hotchkiss,et al. The changing immune system in sepsis , 2013, Virulence.
[20] Drew A. Torigian,et al. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside , 2013, Clinical Cancer Research.
[21] M. Netea,et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? , 2013, American journal of respiratory and critical care medicine.
[22] L. Zitvogel,et al. OncoImmunology: a new journal at the frontier between oncology and immunology , 2012, Oncoimmunology.
[23] J. A. Thomas,et al. The role of innate immunity in spontaneous regression of cancer. , 2011, Indian journal of cancer.
[24] C. Figdor,et al. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. , 2010, Gynecologic oncology.
[25] T. Whiteside,et al. TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.
[26] P. Allavena,et al. Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.
[27] T. Whiteside,et al. Toll-like receptor 4 (TLR4) promotes survival of ovarian cancer cells through induction of cell proliferation and apoptosis resistance , 2008 .
[28] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[29] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[30] C. Figdor,et al. Targeting antigens to dendritic cells in vivo. , 2006, Immunobiology.
[31] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[32] R. Hotchkiss,et al. The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.
[33] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[34] W. Jonas,et al. Fever, Cancer Incidence and Spontaneous Remissions , 2001, Neuroimmunomodulation.
[35] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[36] G QVIST,et al. Spontaneous Regression of Cancer , 1963, British medical journal.
[37] T. Jessy. Immunity over inability: The spontaneous regression of cancer , 2011, Journal of natural science, biology, and medicine.
[38] U. Hobohm,et al. Pathogen-associated molecular pattern in cancer immunotherapy. , 2008, Critical reviews in immunology.
[39] L. Trümper. From bench to bedside , 2005, Medizinische Klinik.